SCHEMBL21883075

SCHEMBL21883075

Cc1cc(N(C)c2ccc3c(c2)c2ccccc2n3C)c2ccccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
HPGD P15428 3/20 0.43
LMNA P02545 2/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
PABPC1 P11940 1/20 0.42
CYP1A2 P05177 1/20 0.41
KDM4E B2RXH2 3/20 0.41
GPR3 P46089 1/20 0.40
ALDH1A1 P00352 2/20 0.40
HTT P42858 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.39
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25992599 0.93 MEN1 (0.46) MAPTHPGDLMNAALOX15TSHR
SCHEMBL23037539 0.92 NCF1 (0.43) MAPTHPGDLMNAALOX15TSHR
SCHEMBL23037565 0.90 PABPC1 (0.43) MAPTHPGDLMNAALOX15TSHR
SCHEMBL23037532 0.87 MAPT (0.48) MAPTHPGDLMNATSHRCYP1A2
SCHEMBL23037533 0.87 NPC1 (0.36) MAPTHPGDLMNAALOX15TSHR
SCHEMBL23037505 0.86 MAPT (0.48) MAPTHPGDLMNAALOX15TSHR
SCHEMBL23037556 0.86 MAPT (0.55) MAPTLMNAALDH1A1HTTMEN1
SCHEMBL23037544 0.85 CYP19A1 (0.47) MAPTHPGDLMNAALOX15KDM4E
SCHEMBL30060724 0.85 CYP19A1 (0.47) MAPTHPGDLMNAALOX15KDM4E
SCHEMBL21883076 0.84 TUBB4A (0.48) MAPTHPGDLMNAALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371417-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties Universite Paris-Saclay (FR) 2025-07-29 US disclosed
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2023-06-29 US disclosed
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2023-06-29 US disclosed
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2023-06-29 US disclosed
EP-3853208-B1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES CENTRE NAT RECH SCIENT (FR) 2023-06-07 EP disclosed
US-11634405-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE (FR) 2023-04-25 US disclosed
US-11634405-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE (FR) 2023-04-25 US disclosed
US-20220023435-A1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES Universite Paris-Saclay (FR) 2022-01-27 US disclosed
US-20210230140-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2021-07-29 US disclosed
US-20210230140-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES Universite Paris-Saclay (FR) 2021-07-29 US disclosed
EP-3784662-A1 COMPOUNDS HAVING A TUBULIN-POLYMERISATION-INHIBITING ACTIVITY AND IMMUNOMODULATORY PROPERTIES Université Paris-Saclay (FR) 2021-03-03 EP disclosed
WO-2020058290-A1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371417-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties TUBB1, TUBB, TUBB3 MAPT 34/4885HPGD 2890/4885LMNA 3653/4885
US-11634405-B2 Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties TUBB1, TUBB, TUBB3 MAPT 34/4885HPGD 2890/4885LMNA 3653/4885
US-20230203005-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES TUBB1, TUBB, TUBB3 MAPT 34/4885HPGD 2890/4885LMNA 3653/4885
US-20220023435-A1 DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES HRH3, ABCC3, ORC3 MAPT 2856/4885HPGD 1779/4885LMNA 2506/4885
US-20210230140-A1 COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES TUBB1, TUBB, TUBB3 MAPT 34/4885HPGD 2890/4885LMNA 3653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.